2025-08-25 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co (LLY) based on the data you provided, formatted for a concise English report with key numerical highlights and commentary:

**Eli Lilly and Co (LLY) Stock Analysis**

Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

**1. Performance vs. S&P 500 (VOO)**

*   **LLY Cumulative Return:** 212.49%
*   **VOO Cumulative Return:** 38.83%
*   **Absolute Spread:** 173.66%
*   **Spread Range:** Max 311.6, Min -27.3, Current 111.0
*   **Relative Spread:** 40.8
*   **Analysis:** LLY has significantly outperformed the S&P 500 over the period examined. The relative spread of 40.8 indicates the current outperformance is positioned in the lower half of its historical range against the S&P 500.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
|------------|---------|---------|---------|--------|--------|
| 2015-2017  | 10.0%   | 56.3%   | 10.0%   | 1.0    | 75.7   |
| 2016-2018  | 39.0%   | 58.6%   | 39.0%   | 1.0    | 103.7  |
| 2017-2019  | 50.0%   | 58.6%   | 50.0%   | 1.0    | 117.8  |
| 2018-2020  | 52.0%   | 58.6%   | 52.0%   | 1.0    | 151.4  |
| 2019-2021  | 106.0%  | 60.6%   | 105.0%  | -0.0   | 247.6  |
| 2020-2022  | 98.0%   | 64.8%   | 109.0%  | -0.0   | 328.0  |
| 2021-2023  | 133.0%  | 64.8%   | 123.0%  | -0.0   | 522.6  |
| 2022-2024  | 150.0%  | 72.2%   | 120.0%  | -0.0   | 692.1  |
| 2023-2025  | 65.0%   | 76.8%   | 20.0%   | 0.0    | 638.0  |

**Analysis:**

*   **CAGR & MDD:** High Compound Annual Growth Rates (CAGR) are observed across different periods, but they are accompanied by significant Maximum Drawdowns (MDD), indicating substantial volatility.
*   **Alpha:** Consistently high Alpha values show that LLY significantly outperforms its benchmark, generating returns above what would be expected based on market movements.
*   **Beta:** Beta values close to 1.0 from 2015 to 2020 suggest that LLY's price moved in tandem with the market. However, the Beta shifts to near 0.0 in more recent years (2019-2025), indicating LLY's price movements have become largely uncorrelated with the overall market.
*   **Cap(B):** Market capitalization shows substantial growth over the years, reflecting the company's expansion.

**2. Recent Stock Price Movement**

*   **Current Price:** 711.68
*   **Previous Close:** 709.82
*   **Change:** 0.26 (Slight increase)
*   **5-Day Moving Average:** 705.64
*   **20-Day Moving Average:** 711.52
*   **60-Day Moving Average:** 757.59
*   **Analysis:** The stock price is slightly above its previous close. The 5-day moving average is below the 20-day moving average, which is below the 60-day moving average. The price is now below the 60-day moving average, which could signal a potential downtrend or consolidation.

**3. Market Risk Indicators & Outlook**

*   **Market Risk Indicator (MRI):** 0.3377 (Low Risk)
*   **RSI:** 37.84 (Not oversold, but trending towards it)
*   **PPO:** 0.65 (Indicates a slight upward trend)
*   **Hybrid Signal:** "cash_1%_Buy 80% of cash (13 shares - Caution - MRI:0.34)" - This suggests a cautious buying signal based on the current indicators.
*   **Recent Relative Spread Change (20 days):** 2.1 (+) - Indicates recent short-term upward momentum.
*   **Expected Return:** 231.4% - Projecting significant long-term outperformance compared to the S&P 500.
*   **Significant price change**: {'price': 711.68, 'previousClose': 709.82, 'change': 0.26} => no special issue

**4. Recent News & Events**

*   **Themes:** Recent volatility, industry trends, regulatory changes, and market events are influencing LLY's stock.
*   **Key Takeaway:** Market experts advise monitoring news and company announcements closely.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-08-07 | 6.30 | 15.56 B$   |
| 2025-05-01 | 3.07 | 12.73 B$   |
| 2024-10-30 | 1.08 | 11.44 B$   |
| 2024-08-08 | 3.29 | 11.30 B$   |
| 2025-08-07 | 3.29 | 11.30 B$   |

**Analysis:** Recent earnings data shows strong EPS and revenue growth, particularly in the latest quarter (2025-08-07).

**6. Financial Information**

**Revenue and Profitability**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-06-30 | $15.56B    | 84.27%        |
| 2025-03-31 | $12.73B    | 82.53%        |
| 2024-12-31 | $13.53B    | 82.24%        |
| 2024-09-30 | $11.44B    | 81.02%        |
| 2024-06-30 | $11.30B    | 80.80%        |

**Capital and Profitability**

| Quarter    | Equity     | ROE      |
|------------|------------|----------|
| 2025-06-30 | $18.27B    | 30.98%   |
| 2025-03-31 | $15.76B    | 17.50%   |
| 2024-12-31 | $14.19B    | 31.07%   |
| 2024-09-30 | $14.24B    | 6.81%    |
| 2024-06-30 | $13.56B    | 21.88%   |

**Analysis:** Revenue and profit margins have been consistently high and increasing, indicating strong financial performance. The ROE also indicates the company is effectively generating profits from its equity.

**7. Overall Assessment**

Eli Lilly and Co. (LLY) has demonstrated significant outperformance compared to the S&P 500. Recent financial data, including earnings, revenue, and profit margins, showcases strong growth. However, the stock exhibits volatility, and market news should be monitored closely. The hybrid signal suggests a cautious buying approach. The long-term expected return is highly positive, indicating potential for substantial future growth, though risks associated with volatility should be considered.
